Mount Sinai Researchers Awarded $16 Million to Develop Antivirals Against Viruses With Pandemic Potential
Leading scientists who study microbiology and emerging pathogens will contribute to several Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern recently established by the NIH
Researchers at the Icahn School of Medicine at Mount Sinai have been awarded an initial $16 million from the National Institutes of Health (NIH) to discover and develop globally accessible and affordable novel oral antivirals to combat COVID-19 and future pandemics.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, recently announced $577 million in funding to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. Researchers from Mount Sinai’s Departments of Microbiology and Pharmacological Sciences, the Global Health and Emerging Pathogens Institute, and the Mount Sinai Center for Therapeutics Discovery will conduct critical research for four of the nine newly established centers, collaborating with other leading researchers at academic institutions across the country.
According to the NIH announcement, AViDD centers will conduct multidisciplinary research to develop candidate COVID-19 antivirals, especially those that can be taken in an outpatient setting, as well as antivirals targeting specific viral families with high potential to cause a pandemic in the future. These include paramyxoviruses, bunyaviruses, togaviruses, filoviruses (including Ebola and Marburg viruses), picornaviruses (including enteroviruses and other cold-causing viruses), and flaviviruses (including the viruses that cause yellow fever, dengue, and Zika).
“We are very excited to continue and expand our previous collaborations with several groups of investigators under the AViDD program for the discovery and advancement of novel antivirals against pathogenic viruses, including SARS-CoV-2,” said Adolfo Garcia-Sastre, PhD, Irene and Dr. Arthur M. Fishberg Professor of Medicine and Director of the Global Health and Emerging Pathogens Institute at Icahn Mount Sinai. “This program fills a major gap in our pandemic preparedness plans.”
The AViDD Centers Mount Sinai researchers will contribute to include:
Center for Antiviral Medicines and Pandemic Preparedness
Dr. Garcia-Sastre will serve as one of the co-principal investigators of the center.
- Project dedicated to discovering inhibitors of SARS-CoV-2 non-enzymatic components
- Dr. Garcia-Sastre is principal investigator; Matthew Evans, PhD, Associate Professor of Microbiology, and Lisa Miorin, PhD, Assistant Professor of Microbiology, are co-investigators.
- Project dedicated to discovering inhibitors of SARS-CoV-2 polymerase
- Christopher Basler, PhD, Professor of Microbiology, is principal investigator; Gustavo Palacios, PhD, Professor of Microbiology, is co-investigator.
- Project dedicated to discovering inhibitors of hemorrhagic fever viruses
-Dr. Basler is co-investigator.
Antiviral Countermeasures Development Center
Project dedicated to developing antivirals that target the polymerase of paramyxoviruses of pandemic concern.
- Benhur Lee, MD, Professor of Microbiology, is principal investigator.
QBI Coronavirus Research Group Pandemic Response Program
Dedicated to bringing together research centers from both academia and industry to pursue the discovery and development of drug therapies for viruses with pandemic potential.
- In Vitro Virology Core: Garcia-Sastre and Ana Fernandez-Sesma, PhD, Professor of Microbiology and Medicine (Infectious Diseases), are co-investigators.
- In Vivo Virology Core: Garcia-Sastre leads this group; Kris White, PhD, Assistant Professor of Microbiology, and Randy Albrecht, PhD, Associate Professor of Microbiology, are co-investigators.
- Medicinal Chemistry Core: Jian Jin, PhD, Mount Sinai Endowed Professor in Therapeutics Discovery, is a co-leader of this core.
AI-Driven Structure-Enabled Antiviral Platform
Dedicated to using cutting-edge technology, such as advanced structural biology, artificial intelligence, machine learning, and computational chemistry, to build a robust antiviral discovery pipeline.
- Antiviral Efficacy and Resistance Core: led by Dr. White; Drs. Garcia-Sastre and Albrecht are co-investigators of the core.
“The AViDD centers will conduct research on the early-stage identification and validation of novel viral targets, with an eye to identifying small molecules and biotherapeutics that directly block viral targets. As drug candidates are identified and evaluated for properties such as potency and breadth, the most promising will enter late-stage preclinical development,” the NIH says in a statement. “Importantly, the centers can draw on the resources of their industry partners to accelerate research, making use of the companies’ chemical libraries and expertise in moving candidates into the product development pipeline.”
”The advent of sophisticated technologies including transcriptomics, proteomics and high-throughput screening of small-molecular-weight compounds has made it possible to rapidly develop novel antivirals against pandemic and other pathogenic viruses. The Global Health and Emerging Pathogens Institute headed by Dr. Garcia-Sastre is at the forefront of these national and international efforts. Through the AViDD Center awards, manyMount Sinai researchers will now be able to lend their expertise to this targeted effort,making a real difference for the future,” said Peter Palese, PhD, Horace W. Goldsmith Professor and Chair of Microbiology at Icahn Mount Sinai.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.